IT is devastating to hear that Kadcyla – a crucial life-extending treatment for women with incurable secondary breast cancer – faces being withdrawn from the NHS, following the failure of NICE and the drug’s manufacturer, Roche, to reach an agreement.
Kadcyla can offer patients precious extra months – even years – of good quality time with their loved ones, with fewer side effects than other treatments.
It is available in many other countries – including France, Germany and Australia – and unless NICE’s draft decision is overturned next month, this fantastic medical advance will bypass patients in England forever.
That’s why I’ve backed Breast Cancer Now’s campaign to #KeepKadcyla, which calls on NICE and Roche to urgently reach a deal to ensure patients in England are not denied this very effective treatment. There is very little time left for this decision to be reversed and I urge NICE and Roche to do everything in their power to keep this drug available.
Anna Kelly
Southcrest
Comments: Our rules
We want our comments to be a lively and valuable part of our community - a place where readers can debate and engage with the most important local issues. The ability to comment on our stories is a privilege, not a right, however, and that privilege may be withdrawn if it is abused or misused.
Please report any comments that break our rules.
Read the rules here